BioCryst Pharmaceuticals, Inc. (BCRX)

NASDAQ: BCRX · USD

$8.35

+0.24 (+3.0%)· Recorded snapshot

Market cap	2.1B
Revenue (ttm)	940.6M
Net income (ttm)	-384.7M
EPS (ttm)	-$1.68
Shares out	255.5M
P/E (forward)	15.9x
Volume	3,333,318
Beta	0.55

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 940.6M
Net income (ttm): -384.7M
EPS (ttm): -$1.68
P/E (forward): 15.9x
Market cap: 2.1B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Aanhouden

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E15.9

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROEn/a

P25 n/aP50 n/aP75 n/a

ROIC138.8

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All BCRX indicators

Market & fundamental data

Available fields

242

Groups with data

Currency

USD

Showing 242 of 242 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0000882796
Company name	BioCryst Pharmaceuticals, Inc.
Country	United States
Country code	US
CUSIP number	09058V103
Earnings date	2026-11-04
Earnings time	bmo
Employees	435
Employees change	-145
Employees growth	-25%
Enterprise value	$2.6B
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	1986
In index	RUSSELL2000
Industry	Drug Manufacturers - Specialty & Generic
IPO date	1994-03-03
Is primary listing	Yes
Is SPAC	No
ISIN number	US09058V1035
Last 10-K release date	2026-02-26
Last earnings date	2026-08-05
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$2.1B
Market cap category	Mid-Cap
Next earnings date	2026-11-04
Options	Yes
Price	$8.35
Price currency	USD
Sector	Healthcare
SIC code	2836
Stock price date	2026-10-28
Symbol	BCRX
U.S. state	North Carolina
Website	https://www.biocryst.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Adjusted P/E ratio	9.71x
Earnings yield	-20.09%
EV/EBIT	6.14x
EV/EBITDA	6.08x
EV/FCF	7.06x
EV/Sales	2.8x
FCF / EV yield	14.17%
FCF yield	17.36%
Forward EV/Sales	3.82x
Forward P/E	15.88x
Forward P/S	3.12x
Industry forward P/E	13.87x
Industry P/E	173.94x
P/(FCF - SBC) ratio	7.16x
P/(OCF - SBC) ratio	7.1x
P/FCF ratio	5.76x
P/OCF ratio	5.72x
P/S ratio	2.29x
Price/EBITDA ratio	4.97x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	45.63%
EBITDA margin	46.04%
FCF margin	39.7%
Gross margin	77.39%
Operating margin	45.63%
Pretax margin	-40.53%
Profit margin	-40.9%
Profit per employee	$-884,306
Profitable quarters	1
Profitable years	1
Revenue per employee	$2.2M
ROA	52.86%
ROA (5Y)	-1.78%
ROCE	122.99%
ROIC	138.77%
ROIC (5Y)	-0.15%
SBC / revenue	7.77%
Tax / revenue	0.37%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth (Q)	1,400%
EPS growth quarters	1
EPS growth years	3
FCF growth	2,268.99%
FCF growth (Q)	153.22%
Gross profit growth	96.28%
Gross profit growth (Q)	38.64%
Gross profit growth 3Y	115.18%
Net income growth (Q)	1,441.69%
Net income growth quarters	1
Net income growth years	3
OCF growth	2,136.64%
OCF growth (Q)	152.63%
Operating income growth	673.96%
Operating income growth (Q)	230.57%
Revenue growth	68.72%
Revenue growth (Q)	33.61%
Revenue growth (QoQ)	39.53%
Revenue growth 10Y	43.62%
Revenue growth 3Y	45.3%
Revenue growth 5Y	64.06%
Revenue growth quarters	22
Revenue growth years	5

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-2.8M
Depreciation and amortization	$3.8M
EBIT	$429.2M
EBITDA	$433M
EPS	$-1.68
FCF per share	$1.46
Financing cash flow	$124.6M
Free cash flow	$373.4M
Free cash flow minus SBC	$300.3M
Gross profit	$727.9M
Income taxes	$3.5M
Investing cash flow	$-448.7M
Net borrowing	$127.5M
Net cash flow	$66.5M
Net income	$-384.7M
Operating cash flow minus SBC	$303M
Operating income	$429.2M
Revenue	$940.6M
Stock-based compensation	$73.1M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	0.52
Book value per share	$-1.78
Debt / EBITDA	1.92
Debt / FCF	2.24
Interest coverage	5.7
Long-term assets	$73.2M
Long-term liabilities	$803.3M
Net cash (debt)	$-484.1M
Net cash / market cap	-22.51%
Net debt / EBITDA	1.12
Net debt / FCF	1.3
Piotroski F-Score	6
Property, plant and equipment	$21.7M
Shareholders' equity	$-454.3M
Tangible book value	$-454.3M
Tangible book value per share	$-1.78
Total assets	$557.9M
Total cash	$352.6M
Total debt	$836.6M
Total liabilities	$1B
WACC	7.22%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	1.85
Current assets	$484.7M
Current liabilities	$208.8M
Current ratio	2.32
Inventory turnover	38.32
Net working capital	$-29.9M
Quick ratio	2.22
Working capital	$275.8M
Working capital turnover	3.78

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-10.24%
Dividend yield	0%
Shareholder yield	-10.24%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	91.18%
10Y return CAGR	6.7%
10Y total return	91.18%
150-day SMA	$9.08
15Y price change	151.22%
15Y return CAGR	6.33%
15Y total return	151.22%
1D price change	3.02%
1M price change	-4.07%
1M total return	-4.07%
1W price change	3.78%
1W total return	3.78%
1Y price change	12.72%
1Y return CAGR	12.73%
1Y total return	12.72%
20-day SMA	$8.06
200-day SMA	$8.73
20Y price change	-27.78%
20Y return CAGR	-1.61%
20Y total return	-27.78%
3M price change	-13.99%
3M total return	-13.99%
3Y price change	55.18%
3Y return CAGR	15.77%
3Y total return	55.18%
50-day SMA	$8.68
50-day SMA vs 200-day SMA	50under200
52-week high	$11.22
52-week high date	2026-07-09
52-week low	$6.23
52-week low date	2026-02-05
5Y price change	-44.81%
5Y return CAGR	-11.21%
5Y total return	-44.81%
6M price change	-7.42%
6M total return	-7.42%
All-time high	$37.25
All-time high date	2000-03-09
All-time low	$0.60
All-time low date	2002-06-26
Average true range (ATR)	$0.32
Average volume	5.1M
Beta (1Y)	0.56
Beta (2Y)	0.62
Beta (5Y)	0.55
Change from 52-week high	-25.62%
Change from 52-week low	33.95%
Change from all-time high	-77.88%
Change from all-time low	1,273.33%
Change from open	3.66%
Day's gap	-0.62%
Dollar volume	$27.8M
High price	$8.44
Low price	$8.05
Monthly RSI	49.11
Open price	$8.05
Position in 52-week range	75.64%
Premarket change	-0.03%
Premarket close	$8.10
Premarket price	$8.10
Premarket volume	9.5K
Previous close	$8.10
Price vs 150-day SMA	-9.28%
Price vs 20-day SMA	2.18%
Price vs 200-day SMA	-5.6%
Price vs 50-day SMA	-5.11%
Relative volume	0.66
RSI	50.59
Sharpe ratio	0.4
Sharpe ratio (3Y)	0.41
Sharpe ratio (5Y)	0.07
Sortino ratio	0.77
Sortino ratio (3Y)	0.79
Sortino ratio (5Y)	0.2
Volume	3.3M
Weekly RSI	46.65
YTD price change	5.64%
YTD total return	5.64%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	222.3M
Float percentage	87%
Shares change (QoQ)	9.46%
Shares change (YoY)	10.24%
Shares held by insiders	0.9%
Shares held by institutions	92.34%
Shares outstanding	255.5M
Short % of float	11.96%
Short % of shares	10.41%
Short ratio	5.2 days

Deeper analysis on BCRX

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this BCRX report

Is a complete BCRX research report available?

No complete published report is available for BioCryst Pharmaceuticals, Inc. (BCRX) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

BioCryst Pharmaceuticals, Inc. (BCRX)

Price

Financial snapshot

Fair-value bridge

Latest news · BCRX

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All BCRX indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on BCRX

Frequently asked questions